American Society of Hematology, Blood, p. blood-2018-04-840090
DOI: 10.1182/blood-2018-04-840090
Full text: Unavailable
Key Points TTP patients who display persistent and severe ADAMTS13 deficiency after remission have a relapse rate of 74% during long-term follow-up. Preemptive rituximab can decrease TTP relapses in 85% of patients with a favorable benefit-risk balance.